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ABSTRACT OF THE THESIS
DEVELOPMENT OF A MALDI-TOF-MS METHOD FOR THE ANALYSIS OF
CYANOBACTERIAL NEUROTOXIN β-N-METHYLAMINO-L-ALANINE (BMAA)
IN SEARCH OF BMAA INCORPORATION IN BIOLOGICAL SAMPLES
by
Laura M. Conklin
Florida International University, 2015
Miami, Florida
Professor John Berry, Major Professor
Beta-N-methylamino-L-alanine (BMAA) is a non-protein amino acid produced by
many cyanobacteria, and thought to induce neurotoxic effects through excitotoxicity,
contributing to neurodegenerative diseases such as Amyotrophic Lateral
Sclerosis/Parkinsonism-dementia complex (ALS-PDC) and Alzheimer’s. The ubiquitous
nature of cyanobacteria, and evidence of biomagnification through our food web, creates
a dire need for the development of an analytical platform that will provide accurate
identification and quantification of BMAA amounts in our ecosystem and potential food
supply. The present study evaluated the ability of a MALDI-ToF-MS method to detect
and quantify BMAA in a variety of biological matrices. Through validation procedures,
it was demonstrated that this MALDI-ToF-MS method provided comparable data to
currently accepted analytical methods, specifically LC-MS/MS. Further, the
development of said method reduced sample preparation and data acquisition time (1-2
seconds per sample), while providing high throughput analysis and eliminating the need
for derivatization, chromatographic separation, and modification of amino acids.

v

TABLE OF CONTENTS
CHAPTER

PAGE

1.

1

INTRODUCTION AND LITERATURE REVIEW
1.1.
1.2.
1.3.
1.4.
1.5.
1.6.
1.7.

SUGGESTED MECHANISM OF BMAA – INDUCED
NEURODEGENERATIVE EFFECTS
COMMON METHODS OF ANALYSIS FOR BMAA
BMAA AND ITS STRUCTURAL ISOMER DAB
LIQUID CHROMATOGRAPHY TANDEM MASS
SPECTROMETRY
HYDROPHILIC INTERACTION LIQUID
CHROMATOGRAPHY (HILIC)
MATRIX ASSISTED LASER DESORPTION IONIZATION
(MALDI)
SPECIFIC AIMS

5
7
12
13
19
20
23

2.

MATERIALS AND SAMPLE PREPARATION
2.1.
MATERIALS
2.2.
SAMPLE PREPARATION
2.2.1. SYNTHESIS OF 13C-BMAA
2.2.2. MALDI MATRIX
2.2.3. STANDARDS FOR METHOD DEVELOPMENT
2.2.4. BMAA AND AMINO ACID STANDARDS
2.2.5. BMAA AND BOVINE SERUM ALBUMIN
2.2.6. ANALYSIS OF BIOLOGICAL TISSUES

23
23
26
26
28
28
28
29
31

3.

ANALYSIS BY LC-MS/MS
3.1.
INSTRUMENTAL PARAMETERS
3.2.
RESULTS/DISCUSSION
3.2.1. ANALYSIS OF STANDARDS
3.2.2. ANALYSIS OF BMAA IN AMINO ACID MATRIX
3.3.
CONCLUSIONS

33
33
36
36
39
48

4.

ANALYSIS BY MALDI-TOF/TOF-MS/MS
4.1.
INSTRUMENTAL PARAMETERS
4.2.
BMAA FULL SCAN ANALYSES
4.2.1. FULL SCAN BMAA ANALYSIS
4.2.2. FULL SCAN BMAA ANALYSIS IN AMINO ACID
MATRIX
4.3.
MALDI-TOF/TOF-MS/MS ANALYSES
4.3.1. ANALYSIS OF STANDARDS
4.3.2. ANALYSIS OF 13C-BMAA
4.3.3. ANALYSIS OF BMAA IN BSA MATRIX
4.3.4. BMAA ANALYSIS IN BIOLOGICAL TISSUES

48
48
50
50

vi

53
54
54
56
58
60

4.4.

4.5.

VALIDATION PROCEDURES
4.4.1. LIMIT OF DETECTION
4.4.2. LIMIT OF QUANTITATION
4.4.3. ACCURACY
4.4.4. PRECISION
4.4.5. RANGE AND LINEARITY
CONCLUSIONS

62
63
64
65
65
66
66

5

DISCUSSION

68

6

LIST OF REFERENCES

71

vii

TABLE LIST
TABLE

PAGE

Table 1. Concentrations of BMAA in different matrices from current literature

9

Table 2. Methods of detection and quantitation of BMAA in biological samples
in current literature

15

Table 3. Amino Acid Standard Composition

25

Table 4. Peak intensities analytical background response at 102 m/z

63

Table 5. Calculated values for percent recovery

65

viii

FIGURE LIST
FIGURE

PAGE

Figure 1. Chemical structure of the non-protein amino acid BMAA, produced
by over 90% of cyanobacteria.

3

Figure 2. Possible mechanism of BMAA misincorporation into proteins, as
discussed by Dunlop, et al. in 2013 (Dunlop et al., 2013)

7

Figure 3. Chemical structures of β-N-methylamino-L-alanine (BMAA) and
its structural isomer 2-4-diaminobutyric acid (DAB)

12

Figure 4. Proposed mechanism of HILIC separation by Buszewski et al., 2012
(Buszewski et al, 2012).

20

Figure 5. Schematic diagram of MALDI-ToF-MS/MS instrument in reflector
mode

22

Figure 6. Proposed mechanism of 13C-BMAA

26

Figure 7. 1H-NMR spectra of unlabeled BMAA (top figure) and 13C-BMAA
(bottom figure). The singlet peak at 3.083 ppm is absent in the
unlabeled BMAA.

27

Figure 8. Microwave-assisted acid hydrolysis set-up

30

Figure 9. Acid Hydrolysis Apparatus

32

Figure 10. Sample preparation schematic of biological tissues with a solid
phase extraction clean-up for the quantitative analysis of BMAA by
MALDI-TOF/TOF-MS/MS

33

Figure 11. LC-MS/MS spectra of BMAA, DAB, and 13C-BMAA standards

35

Figure 12. Representative LC-MS/MS calibration curve for the concentration
ratios of BMAA to 13C-BMAA (IS) in ppm against the peak area
ratios of BMAA to 13C-BMAA (IS)

37

Figure 13. Representative LC-MS/MS calibration curve for the concentration
ratios of BMAA to DAB (IS) in ppm against the peak area ratios of
BMAA to DAB (IS)

37

Figure 14. Representative LC-MS/MS calibration curve for the concentration
ratios of BMAA to DAB (IS) in ppm against the peak area ratios of
BMAA to DAB (IS)

38

ix

Figure 15. Representative LC-MS/MS calibration curve for the concentration
ratios of BMAA to DAB (IS) in ppm against the peak area ratios of
BMAA to DAB (IS). The transitions for BMAA and DAB are
119.033>76.1 m/z and 119.033>101.2 m/z, respectively

38

Figure 16. Chromatograms of water blanks, 0ppm BMAA and
0.05ppm BMAA standards with 1ppm spikes of 13C-BMAA and
DAB as internal standards. BMAA transitions 119.033>102.2 m/z
and 119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z
are shown above. Compliments of the Advanced Mass Spectrometry
Facility, FIU
40
Figure 17. Chromatograms of 0.1ppm, 0.25ppm, and 0.5ppm BMAA standards
with 1ppm spikes of 13C-BMAA and DAB as internal standards.
BMAA transitions 119.033>102.2 m/z and 119.033>76.1 m/z and
13C-BMAA transition 120.062>103.1 m/z are shown above.
Compliments of the Advanced Mass Spectrometry Facility, FIU

41

Figure 18. Chromatograms of 0ppm and 1ppm BMAA standards with 1ppm
spikes of 13C-BMAA and DAB as internal standards and 0ppm
BMAA in an amino acid matrix with the same concentrations of
internal standards (13C-BMAA and DAB). BMAA transitions
119.033>102.2 m/z and 119.033>76.1 m/z and 13C-BMAA transition
120.062>103.1 m/z are shown above. Compliments of the Advanced
Mass Spectrometry Facility, FIU
42
Figure 19. Chromatograms of 0.1ppm, 0.25, and 0.5ppm BMAA in an amino
acid matrix with 1ppm spikes of both internal standards (13C-BMAA
and DAB). BMAA transitions 119.033>102.2 m/z and 119.033>76.1
m/z and 13C-BMAA transition 120.062>103.1 m/z are shown above.
Compliments of the Advanced Mass Spectrometry Facility, FIU
43
Figure 20. Chromatograms of water blank, 0.0ppm and 0.05ppm BMAA
standards with 1ppm spikes of 13C-BMAA and DAB as internal
standards. BMAA transitions 119.033>102.2 m/z and 119.033>76.1
m/z and DAB transition 119.033>101.2 m/z are shown above.
Compliments of the Advanced Mass Spectrometry Facility, FIU

44

Figure 21. Chromatograms of 0.1ppm, 0.25ppm and 0.5ppm BMAA standards
with 1ppm spikes of 13C-BMAA and DAB as internal standards.
BMAA transitions 119.033>102.2 m/z and 119.033>76.1 m/z and
DAB transition 119.033>101.2 m/z are shown above. Compliments
of the Advanced Mass Spectrometry Facility, FIU

45

x

Figure 22. Chromatograms of 0ppm and 1ppm BMAA standards with 1ppm
spikes of 13C-BMAA and DAB as internal standards and 0ppm
BMAA in an amino acid matrix with the same concentrations of internal
standards (13C-BMAA and DAB). BMAA transitions 119.033>102.2
m/z and 119.033>76.1 m/z and DAB transition 119.033>101.2 m/z
are shown above. Compliments of the Advanced Mass Spectrometry
Facility, FIU
46
Figure 23. Chromatograms of 0.1ppm, 0.25, and 0.5ppm BMAA in an amino
acid matrix with 1ppm spikes of both internal standards (13C-BMAA
and DAB). BMAA transitions 119.033>102.2 m/z and 119.033>76.1
m/z and DAB transition 119.033>101.2 m/z are shown above.
Compliments of the Advanced Mass Spectrometry Facility, FIU
47
Figure 24. Image of 384 well MALDI Plate

49

Figure 25. Positive Ion MALDI-TOF-MS spectrum of BMAA and
methyltyrosine (IS) with CHCA as the matrix. BMAA Concentrations
ranged from 0-300μM and methyltyrosine was at 200μM. The BMAA
parent ion is seen at 119 m/z and the methyltyrosine parent ion
at 196 m/z
51
Figure 26. Representative calibration curve for the concentrations of BMAA in
μM against the peak intensity ratios of BMAA to methyltyrosine (IS)
with CHCA as the MALDI matrix. Parent ions for BMAA and
methyltyrosine were 119 and 196, respectively
53
Figure 27. Representative calibration curve for the concentrations of BMAA in
μM against the peak intensity ratios of BMAA to methyltyrosine (IS)
in an amino acid matrix, with CHCA as the MALDI matrix. Parent
ions for BMAA and methyltyrosine were 119 and 196, respectively
54
Figure 28. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and
DAB (IS) with CHCA as the matrix. BMAA Concentrations ranged
from 0-25ppm and the concentration of DAB was at 25ppm. The
BMAA fragment ion is seen at 102 m/z and the DAB fragment ion
at 101 m/z

55

Figure 29. Representative calibration curve for the concentrations of BMAA in
ppm against the peak intensity ratios of BMAA to DAB (IS) with
CHCA as the MALDI matrix. Parent ions for BMAA and DAB are
119 and their respective fragments are 102 and 101. Concentrations
of BMAA ranged from (0-25ppm) and the concentration of DAB was
25ppm. Error bars were calculated using the standard deviation
56

xi

Figure 30. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB
(top), and 13C-BMAA (bottom) with CHCA as the matrix. BMAA
Concentration was at 300μM, the concentration of DAB was 100μM,
and the concentration of 13C-BMAA was at 300μM. The BMAA
fragment ion is seen at 102 m/z, DAB at 101 m/z, and 13C-BMAA at
103 m/z
57
Figure 31. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA (top) and
13C-BMAA (bottom) with CHCA as the matrix. BMAA Concentration
was at 300μM and the concentration of 13C-BMAA was at 300μM.
The BMAA fragment ions are seen at 73 m/z and 43.8 m/z, and
13C-BMAA at 74 m/z and 44.7 m/z
58
Figure 32. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB
(IS) in a hydrolyzed BSA solution with CHCA as the matrix. BMAA
concentrations ranged from 0-125ppm, and the concentration of DAB
in each spectra was 50ppm. The fragment ions are seen at 102 m/z for
BMAA and 101 m/z for DAB. Note that below 125ppm, the peak for
BMAA at 102 m/z is split into two peaks at 102 m/z and 103 m/z and
the signal intensity is greatly reduced
59
Figure 33. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB
(IS) in a hydrolyzed biological tissue (shrimp) with CHCA as the matrix.
Spiked BMAA concentrations ranged from 0-200ppm, and the
concentration of DAB in each spectra was 25ppm. The fragment ions
are seen at 102 m/z for BMAA and 101 m/z for DAB
61
Figure 34. Representative standard addition calibration curve for the
concentrations of BMAA in ppm against the peak intensity ratios of
BMAA to DAB (IS) with CHCA as the MALDI matrix. Parent ions
for BMAA and DAB are 119 and their respective fragments are 102
and 101. Spiked concentrations of BMAA ranged from (0-200ppm)
and the concentration of DAB was 25ppm. Error bars were calculated
using the standard deviation. The calculated concentration of BMAA
in the unspiked sample is 234.52ppm
62

xii

Figure 35. Representative calibration curve for the concentrations of BMAA in
ppm against the peak intensity ratios of BMAA to DAB (IS) with
CHCA as the MALDI matrix. Parent ions for BMAA and DAB are
119 and their respective fragments are 102 and 101. Concentrations of
BMAA ranged from (0-25ppm) and the concentration of DAB was
25ppm. Error bars were calculated using the standard deviation. Limit
of detection and limit of quantitation were calculated by the
measurement of the ratios of peak intensities of fragment ion 102 m/z
over 101 m/z in the background response of the blank
(5 replicates)
64

xiii

ACRONYMS AND ABBREVIATIONS
AAS
ACN
ALS
ALS/PDC
AQC
BMAA
BSA
DAB
DTT
GC-MS
HESI
HILIC
HPLC
LC-MS
LOD
LOQ
MALDI
MALDI-IMS
MALDI-ToF-MS

m/z
MeOH
MRM
MS/MS
N
NMR
RT
SIM
SRM
TFA
TSQ
Ultrapure Water

Amino Acid Standard
Acetonitrile
Amyotrophic Lateral Sclerosis
Amyotrophic Lateral
Sclerosis/Parkinsonism Demetia Complex
6-aminoquinolyl-N-hydroxysuccinimidyl
carbamate
β-N-methylamino-L-alanine
Bovine Serum Albumin
2,4-diaminobutyric acid
Dithiothreitol
Gas Chromatography – Mass
Spectrometry
Heated Electrospray Ionization
Hydrophilic Liquid Interaction
Chromatography
High Performance Liquid
Chromatography
Liquid Chromatography – Mass
Spectrometry
Limit of Detection
Limit of Quantitation
Matrix Assisted Laser Desorption
Ionization
Matrix Assisted Laser Desorption
Ionization – Imaging Mass Spectrometry
Matrix Assisted Laser Desorption
Ionization – Time of Flight – Mass
Spectrometry
Mass-to-charge ratio
Methanol
Multiple Reaction Monitoring
Tandem Mass Spectrometry
Nitrogen
Nuclear Magnetic Resonance
Retention Time
Selected Ion Monitoring
Selective Reaction Monitoring
Trifluoroacetic acid
Triple Quadrupole
18MΩ water

xiv

1. INTRODUCTION AND LITERATURE REVIEW
The connection between β-N-methylamino-L-alanine (BMAA) and Amyotrophic
Lateral Sclerosis/Parkinsonism-dementia complex (ALS-PDC) came to light in 1953
when a medical report was released stating that on the island of Guam, the incidence rate
of ALS-PDC among the native Chamorro people was 100-fold higher than anywhere else
in the world (Arnold et al., 1953). In this report, however, it was thought that genetic
variations among the Chamorro people was the causative factor for the increased
incidence of ALS-PDC (Arnold et al., 1953). Once researchers failed to correlate a
genetic causation to the increased incidence of ALS-PDC, they turned to possibility of
environmental factors being the cause (Spencer et al., 1986). The Chamorro people
consume a diet that relies heavily the seeds of the native Cycad tree to produce flour
(Murch et al., 2004). It was then suggested that the consumption of these seeds from the
Cycad tree was the cause of the increased rate of this specific neurodegeneration among
the Chamorro people, deeming this hypothesis as, “The Cycad Hypothesis” (Murch et al.,
2004).
It was not until 1967 in a study conducted by Vega et al, that BMAA was isolated
from the seeds of the cycad tree and found to have neurotoxic effects after being injected
into chicks and rats, causing symptoms that paralleled that of patients suffering from
neurodegenerative diseases such as ALS-PDC and Alzheimer’s (Vega et al., 1967).
Various studies done on rats, chicks, macaques, and mice, further supported a new
hypothesis that BMAA was the component of the cycad seeds that was the causative
agent of neurodegeneration. At this point in time, the origin of BMAA was still
unknown. In 2003, it was found that BMAA was a non-protein amino acid that was
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being produced by the cyanobacterial genus Nostoc as a symbiont to the coralloidal roots
of the cycad tree (Murch et al., 2004). Figure 1 depicts the chemical structure of BMAA.
In this study, by Murch, et al. (2004), not only was BMAA identified as a product of this
cyanobacteria, but evidence of biomagnification through the cycad tree and further into
the food web to the Chamorro people was seen. By analyzing various portions of the
cycad tree (i.e., roots, leaves, and seeds) and the hair and skin of a species of Flying Fox,
a type of fruit bat, that forages on the seeds, levels of BMAA were seen to have increased
along the food web, accumulating along the way, until finally being consumed by the
Chamorro people either through flour produced from the seeds of the cycad, or by the
Flying Foxes who forage on the fruit and seeds of the Cycad tree (Murch et al., 2004).
Further, this study found the presence of BMAA in brain tissues of patients who had
suffered not only from ALS-PDS, but Alzheimer’s as well (Murch et al., 2004). These
findings provided evidence for the theory of the biomagnification of BMAA among food
webs and also pushed for further research as to the role of BMAA in neurodegenerative
diseases (Murch et al., 2004). Other subsequent studies found that 90% of cyanobacterial
species produced BMAA, suggesting that human exposure to this neurotoxin might be
much more prevalent than previously thought (Cox et al., 2005). Recent studies showing
BMAA present in tissues of some of the top predators such as mussels and shark fins,
suggest that the ability of this amino acid to biomagnify, could prove to be a serious risk
to the entire human population, if the mode of action of the neurotoxin is the cause of
many neurodegenerative diseases (Mondo et al., 2012).
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Figure 1. Chemical structure of the non-protein amino acid BMAA, produced by over
90% of cyanobacteria.

Currently, there is very little consensus as to a method of detection as well as an
accurate technique for the analysis of BMAA. The only true consensus regarding BMAA
are the neurotoxic effects that it has on a cellular level based on in vivo studies, however,
the link between BMAA and ALS has yet to be effectively demonstrated in an animal
model (Karamyan et al., 2008; Duncan et al., 1991). The ubiquitous nature of
cyanobacteria and evidence of biomagnification through our food web, creates a need for
researchers to clearly understand the mode of action by which BMAA exerts itself on
primary motor neurons, and the development of an analytical platform that will provide
accurate identification and quantification of BMAA amounts in our ecosystem and
potential food supply. The present project entails the development of an analytical
method using MALDI-ToF/ToF-MS/MS that ensures the accurate identification and
quantification of BMAA with minimal sample preparation. By method development,
clear reporting, validation and inter-laboratory comparisons, the discrepancies that
currently exist regarding previous studies are diminished. The development of such
analytical platform aims to give researchers a better understanding of the extent or
magnitude of human exposure to BMAA.
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The aim of the current research is to provide an evaluation of MALDI-ToF/ToFMS/MS as an analytical platform for the identification and quantification of BMAA in a
variety of matrices. The research involves method development, validation studies, and
subsequent employment to evaluate relevant biological samples from South Florida
waters, where BMAA accumulation has been previously reported. The MALDI-TOF
technique was found to effectively measure BMAA in a range of biological matrices, and
moreover, was notably able to discriminate, specifically by means of so-called MALDITOF/TOF, BMAA from diaminobutyric acid (DAB), a structural isomer also produced
by cyanobacteria, which has been suggested to potentially confound analytical results.
The details of the techniques, including analytical results obtained from application to
biological samples from South Florida waters, comparison to conventional (e.g. liquid
chromatography/mass spectrometry) techniques and potential for understanding toxicity
of BMAA will be discussed.
The goal of developing a MALDI-TOF/TOF-MS/MS method is to offer another
analytical platform that allows for minimal sample preparation, rapid analysis, while
eliminating the need for derivatization, chromatographic separation and modification of
amino acids. If the proposed method were to be coupled to MALDI imaging mass
spectrometry (IMS), accurate quantitation of BMAA along with visual spatial
localization would be possible.
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1.1. SUGGESTED MECHANISM OF BMAA – INDUCED
NEURODEGENERATIVE EFFECTS

On the basis of the current literature, there are many differences in opinion as to what
the mode of activity BMAA puts forth on neuronal cells, however, many studies have
shown significant evidence that BMAA has the capability of crossing the blood-brain
barrier, competitively binding to glutamate receptors, causing chemical and cellular ion
shifts that lead to depolarization, excitotoxicity, and eventually neuronal cell apoptosis
(Duncan et al., 1991; Lobner et al., 2007; Cucchiaroni et al., 2010) In 1991, Duncan, et
al. (1991) studied the pharmacokinetics and the permeability of the blood-brain barrier,
and were able to show that in a rat model, BMAA can cross the blood-brain barrier by an
L-type amino acid carrier. Lobner, et al. (2007) conducted a study in 2007 in which they
looked that the synergistic effects of low doses of BMAA with amyloid-β and MPP+,
both known neurotoxins. Their study provided data suggesting that BMAA acts on
NMDA receptors and another particular glutamate receptor (mGluR5) (Lobner et al.,
2007). One other notable study was done by Cucchiaroni, et al. (2010) in which they
found that an injection of BMAA caused an increase in Ca+, increased production of
reactive oxygen species (ROS), and the heavy release of cytochrome-c into the cytosol in
a rat neuron model. The release of cytochrome-c could account for diminished
mitochondrial activity, excitotoxicity, and cellular apoptosis. In conclusion, after BMAA
is consumed or ingested, it passes through the blood-brain barrier via L-type amino acid
carriers, and then competitively binds to NMDA receptors along with other glutamate
receptors (Cucchiaroni et al., 2010). The binding of BMAA to NMDA and other
glutamate receptors then causes cellular ion shifts of Ca+, Na+, and K+, an increase in
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ROS production, depolarization of the cell, and a heavy release of cytochrome-c
(Cucchiaroni et al., 2010). This so called “excitotoxicity” mechanism could be the
causative mode of activity of BMAA on neuronal cells, leading to many
neurodegenerative diseases.
More recently, and perhaps more notable, in a study done by Dunlop, et al. (2013),
researchers incubated multiple types of human cells with 3H-BMAA and unlabeled
BMAA and were able to determine that not only does BMAA become misincorporated
into human proteins, but binding of BMAA is inhibited by L-serine. Further, the study
showed that the formation of autofluorescent bodies, that are characteristic of protein
aggregation, was diminished by the co-incubation of BMAA and L-serine with human
cells (Dunlop et al., 2013). The diminished presence of autofluorescent bodies with the
co-incubation of BMAA and L-serine, suggests that the misincorporation of BMAA into
human cells is a protein-synthesis dependent process (Dunlop et al., 2013). Figure 2
shows the possible mechanism of BMAA misincorporation via a protein-synthesis
dependent process (Dunlop et al., 2013). It must be noted that the mechanism by which
BMAA becomes incorporated into proteins and crosses the blood-brain barrier is still
debated, however L-type amino acid transport has been suggested, and the studies
described above are progressive steps to understanding the true mechanism by which
BMAA acts.
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Figure 2. Possible mechanism of BMAA misincorporation into proteins, as discussed by
Dunlop, et al. in 2013 (Dunlop et al., 2013).

1.2. COMMON METHODS OF ANALYSIS FOR BMAA
Current methodology for the analysis of BMAA in a variety of biological matrices
and mixtures of amino acids prepared by splitting proteins by means of acid hydrolysis,
commonly referred to as protein hydrolysates, primarily include, high performance liquid
chromatography with postcolumn fluorescence detection (HPLC-FLD), liquid
chromatography mass spectrometry (LC-MS), and liquid chromatography tandem mass
spectrometry (LC-MS/MS) using both derivatized and underivatized BMAA samples
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(Faassen et al., 2012; Karlsson et al., 2012; Faasen et al., 2013). The reported
incorporation of BMAA into proteins, in protein hydrolysates, led to the universal use of
hydrolysis procedures to account for all BMAA in a sample (bound and free). All of
these methods employ liquid chromatography, separating a mixture using a liquid mobile
phase that carries the mixture through a stationary phase within a chromatographic
column and further into a detector or mass spectrometer. Researchers over the past
decade have utilized a variety of methods and protocols regarding which analytical
method produces data to best quantify BMAA in biological samples, and therefore, the
published data has suggested to potentially overestimate and/or fail to detect BMAA in a
sample. Table 2 depicts the variety of analytical techniques that some research groups
have used; the majority of research groups have chosen LC-MS/MS (Table 2).
Table 1 describes the reported concentrations of BMAA in various matrices. Over
the last fifteen years, researchers have analyzed multiple samples that vary from cycad
seeds to very complex matrices such as lobsters and brain tissues. The amount of BMAA
found in these matrices, varies from 0μg/g to 2,286μg/g (Table 1) (Banack et al., 2014;
Brand et al., 2010; Christensen et al., 2012; Faasen et al., 2009; Karlsson et al., 2014;
Mondo et al., 2014; Spacil et al., 2010).
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Table 1. Concentrations of BMAA in different matrices from current literature.
CITATION

METHOD

BMAA (μg/g)

SAMPLE TYPE

Fassen 2009

LC-MS/MS

4-42

Brand 2010

LC-MS/MS

275-2,286

Spacil 2010

HPLC-MS/MS

0-109.4

Christensen 2012

LC-MS/MS

19.1-50.1

Mondo 2014

HPLC-FD

86-265

Cyanobacterial
blooms in Dutch
urban waters
Blue Crab, oyster,
Puffer Fish, shrimp,
White Perch
Prokaryotic
cyanobacterium to
Eukaryotic fish
Cycad, oyster, Blue
Crab
Shark cartilage
dietary supplements

Karlsson 2014

HPLC-MS/MS
HPLC-MS/MS

75-352
0.023-245.978

Banack 2014

LC-MS/MS

0.4-27

Liver and brain
samples of rats
Lobsters from
Florida

In most of the first studies in the early 2000’s, researchers began using 6aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) derivatization prior to HPLCFLD (Banack et al., 2003; Cox et al., 2003; Murch et al., 2004). Derivatizing agent,
AQC adds a fluorescent “tag” to BMAA, making it detectable HPLC-FLD methods
(Banack et al., 2003; Cox et al., 2003; Murch et al., 2004; Faassen et al., 2012; Mondo et
al., 2012; Mondo et al., 2014). Similarly, Esterhuizen-Londt (2011) used another
derivatization method using propyl chloroformate, EZ-faast™. The HPLC-FLD method
has its drawbacks, which are discussed below. Murch et al. (2004) discovered that
BMAA can also be incorporated into proteins in samples, and requires hydrolysis to
release the amino acid from its bound form. The discovery of protein incorporation
accounted for an underestimation of BMAA in biological samples in previous studies.
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Faasen, et al. (2012) compared three analytical techniques, HPLC-FLD and LCMS/MS using derivatized and underivatized samples (Faasen et al., 2012). Following the
literature of comparative analytical methods of BMAA analysis in the present study, LCMS/MS using derivatized samples (to reduce polarity), or underivatized samples, proved
to be more accurate than HPLC-FLD, on the basis of its higher selectivity: four different
selective criteria are required rather than the two required by HPLC-FLD (Faasen et al.,
2012). The two selectivity criteria required for HPLC include a fluorescent signal by
derivatization with AQC (AccQ-Taq) (the derivatization method that makes the
derivatives more stable than the original amino acids and adds a fluorescent tag for
analysis), and retention time, whereas the four selective criteria of LC-MS/MS are
retention time, two separate mass to charge ratios (m/z) based on precursor and product
ions, and product ion abundance ratio (Faasen et al., 2012). The lower selectivity of
HPLC-FLD and LC-MS led to the detection of higher concentrations of BMAA than LCMS/MS, however, this was likely a result of lower selectivity and the false positives of
other amino groups that fluoresced with AQC or other derivatization methods (Faasen et
al., 2012). There has been little research done between labs to use different published
methods to analyze the same set of samples, therefore, creating many discrepancies
between data sets. There has yet to be a single method or interlaboratory evaluations of
methods. The magnitude of potential human exposure is still unknown therefore, because
of the wide range of data.
In a study done by Karlsson, et al. (2012) researchers used Matrix Assisted Laser
Desorption Ionization – imaging mass spectrometry (MALDI-IMS) in an effort to image
and study protein changes in the brains of adult rats after exposure to BMAA during the
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neonatal period. The instrumental method MALDI/IMS works by using dyes to
accentuate proteins of interest, and by taking images at different stages, MALDI allows
researchers to see protein changes (Karlsson et al., 2012). Not only does MALDI-IMS
provide spatial localization of multiple proteins, but this instrument has the capability to
provide a rough estimate of the quantity of protein or analyte of interest in one location.
Karlsson, et al. (2012) looked at different sections of brain tissue and saw multiple
changes in proteins using this method. The study by Karlsson, et al. (2012) in particular
provided data suggesting that BMAA changes various proteins in the hippocampus along
with neurodegenerative symptoms and neuronal cell apoptosis.
Thus far, matrix assisted laser desorption time of flight mass spectrometry (MALDIToF/ToF-MS/MS), has not been used for the quantitative analysis of BMAA, however,
research has been done using MALDI-ToF/ToF-MS/MS to quantify other small
molecules, including other amino acids (Alterman et al., 2004; Cohen et al., 2014; Dong
et al., 2010; Gobey et al., 2005; Gogichaeva et al., 2006). Both HPLC-FLD and LCMS/MS require extensive sample preparation, derivatization, acid hydrolysis, reversephase elution for separation, and a data acquisition time of 27 minutes (Faasen et al.,
2012). If MALDI-ToF-MS proves to be a successful method for the quantification and
qualification of BMAA, it would reduce the time for sample preparation and data
acquisition to only a few seconds per sample, provide high throughput analysis, and
would eliminate the need for derivatization, chromatographic separation, and
modification of amino acids (Gogichaeva et al., 2012). Furthermore, coupling MALDIToF-MS to MALDI-IMS could be innovative in terms of imaging the location of BMAA
in biological systems while quantifying the concentrations in these locations.
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1.3. BMAA AND ITS STRUCTURAL ISOMER DAB
Banack et al. (2010) published a paper discussing a structural isomer of BMAA that
often co-exists in nature. This structural isomer, 2-4-diaminobutyric acid (DAB) has the
same mass as BMAA (118.13 m/z), but has a different structure and fragment ions
(Figure 3) (Banack et al., 2010). The fragment ions of BMAA are 119 m/z to 102 m/z
and 76 m/z, whereas the fragment ions for DAB are 119 m/z to 101 m/z and 74 m/z,
respectively. The co-occurrence of BMAA and DAB, and the inability for HPLC-FLD
and LC-MS to distinguish the structural isomers could lead to overestimation of BMAA
in a biological sample. The amino acid DAB, is another non-protein amino acid that was
first discovered, in a variety of antibiotics, as a bacterial metabolic product, and is
commonly found in both prokaryotes and eukaryotes (Banack et al., 2010). Since 2010,
many research groups have successfully separated BMAA from DAB to provide more
accurate data on the quantitation of BMAA in biological samples.

Figure 3. Chemical structures of β-N-methylamino-L-alanine (BMAA) and its structural
isomer 2-4-diaminobutyric acid (DAB)
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1.4. LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY
Chromatography, whether it be liquid or gas, is the separation of a mixture or solution
based on three interactions: the mobile phase, the stationary phase, and the analytes
within the mixture. Liquid chromatography uses a liquid mobile phase, as the name
suggests, and carries the mixture through a column that contains a stationary phase.
Within this column, the analytes in the mixture interact with the stationary phase, passing
through the column at different times. The relative affinity of the analyte to the
stationary phase determines the time in which it will elute, or its retention time. On the
basis of an analytes chemical structure and polarity, it will interact differently with the
mobile phase and surface of the stationary phase. These differences in interaction, result
in different retention times of components in a mixture. Liquid chromatography is
commonly used in the study of natural products and toxins.
The type of mobile phase must be carefully selected. Common mobile phases used in
liquid chromatography are acetonitrile, dioxane, ethanol, methanol, isopropanol,
tetrahydrofuran, and water (Buszewski et al., 2012). Additives such as formic acid may
be mixed into water or acetonitrile to shift the polarity of the mobile phase (Buszewski et
al., 2012). For the analysis of BMAA, multiple mobile phases have been used, but are
also dependent on the stationary phase of the column (Table 2). Table 2, illustrates
common mobile phases that have been used for the study of BMAA in biological
samples, along with chromatographic columns that have been used for each mobile
phase. For the study of amino acids, particularly BMAA, a combination of acetonitrile,
water, and a dilute acid is typically used (Murch et al., 2004).
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The column used for amino acid analysis is dependent on the mobile phase,
composition and polarity of the analyte, derivatization, and whether positive or negative
mode is used. Research groups who have used AQC derivatization, typically use a C18
column, whereas groups who analyze BMAA in its natural form, or underivatized,
typically use a hydrophilic Interaction liquid chromatography (HILIC) column.
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Table 2. Methods of detection and quantitation of BMAA in biological samples in current literature.
Reference

Analytical
Quantitation
Method
LC-MS &
HPLC-FLD

Derivatiza
tion
Method
AQC

Rosen (2008)

LC-MS/MS

NONE

Zic®-HILIC (5μm,
50x2.1mm)

Faassen (2009)

LC-MS/MS

NONE

Zic®-HILIC (5μm,
2.1x150mm)

65% ACN, 35% water and
0.1% FA

Spacil (2010)

LC-MS/MS

AQC

Hypersil GOLD C18

Brand (2010)

LC-MS/MS

AQC

EsterhuizenLondt (2011)

LC-MS

EZ:
faast™
amino acid
analysis kit

Thermo Hypersil
GOLD
(100mmx2.1mm, 3μm
particle column)
Phenomenex AAAMS 250x2.0mm

0.1% FA in water and ACN
(93:7) (mobile phase A), 0.1%
FA in ACN (mobile phase B)
0.1% FA in water (mobile
phase A), 0.1% FA in ACN
(mobile phase B)

Murch (2004)

Column ID

Mobile Phase

Instrument

Waters Nova-Pak C18

140mM sodium acetate,
5.6mM trimethylamine pH 5.2
(mobile phase A), 60% ACN
in water (mobile phase B)
ACN and 60mM FA in water

Agilent liquid
chromatography
mass spectrometer,
single quad, DAD
Micromass Quattro
Ultima or API
4000 QTRAP and
Waters Alliance
2690 or Agilent
1100
Agilent 1200 LC
and an Agilent
G6410A QQQ
API 2000™ LCMS/MS QQQ
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10mM ammonium formate in
water (mobile phase A),
10mM ammonium formate in
methanol (mobile phase B)

QQQ, Waters 2475
Multi-λFluorescence
Detector
Shimadzu LC
20AB and
Shimadzu 2010
EV

Christensen
(2012)

LC-MS/MS

AQC

Waters Xbridge
4.6x150mm C18
column

Proprietary Waters AccQ-Tag
Ultra Eluents

Glover (2012)

LC-TOF-MS

AQC

Waters amino acid
analysis column
(100x2.1mm; 1.7μm,
C18)

0.1% FA in water (mobile
phase A), ACN (mobile phase
B)

Faassen (2012)

LC-MS/MS
(derivatized
and
underivatized)
and HPLCFLD

NONE and
AQC

Mondo (2012)

LC-MS/MS
and HPLDFLD

AQC

LC-MS/MS:
(derivatized) Zorbax
Eclipse AAA
(4.6x75mm, 3.5μm
column)
(underivatized) Zic®HILIC (2.1x150mm,
5μm diameter column)
HPLC-FLD: NovaPak C18 (3.9x300mm,
4μm column)
Waters Nova-Pak C18
column
(3.9mmx300mm)

LC-MS/MS: ACN with 0.1%
FA (mobile phase A),
Millipore water and 0.1% FA
(mobile phase B)
HPLC-FLD: 140mM sodium
acetate and 5.6mM
trietylamine in Millipore water
pH 5.2 (mobile phase A),
ACN (mobile phase B),
Millipore water (mobile phase
C)
LC-MS/MS: Aqueous 0.1%
FA (mobile phase A), 0.1%
FA in ACN (mobile phase B)
HPLC-FLD: 140mM sodium
acetate, 5.6mM trietylamine,
pH 5.2 (mobile phase A), 52%
ACN in water (mobile phase
B)
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Agilent
Technologies 1200
LC with an Agilent
Technologies
G6410A QQQ
Single quadrapole
mass spectrometer
(Waters EMD
1000) TOF-MS;
Waters LCT
Premier
LC-MS/MS:
Agilent 1200LC
and Agilent 6401A
QQQ
HPLC-FLD:
Agilent 1100 LCFLD

LC-MS/MS:
Triple quadrupole
system
HPLC-FLD:
Waters 2475 Multi
λ-Fluorescence
Detector

Jiang (2012)

LC-MS/MS

AQC

HPLC: Hypersil
GOLD C18 column
(100x2.1mm, 3μm
particle size)
UHPLC: Agilent
Bonus RP Rapid
Resolution High
Throughput (RRHT)
column (100x2.1mm,
1.8μm particle size)
ACCQ-TAG™
ULTRA C18 column
(100x2.1mm, 1.7μm
particle size)
Waters AccQTag
Ultra C18 column
(2.1x100mm)

HPLC: 5% ACN in water
with 0.3% acetic acid and
0.0005% TFA (mobile phase
A), ACN with 0.3% acetic acid
and 0.005% TFA (mobile
phase B)
UHPLC: 0.1% FA in water
(mobile phase A), 0.1% FA in
ACN (mobile phase B)

Triple quadrupole
system

Jiang (2013)

LC-MS/MS

AQC

5% ACN in water with 0.3%
acetic acid (mobile phase A),
ACN with 0.3% acetic acid
(mobile phase B)
Aqueous 0.1% FA (mobile
phase A), and 0.1% FA in
ACN (mobile phase B)

TSQ Vantage
triple quadrupole
mass spectrometer

Dunlop (2013)

LC-MS/MS

AQC

Masseret
(2013)

LC-MS/MS

AQC

Waters AccQTag
Ultra column
(2.1x100mm)

Aqueous 0.1% FA (mobile
phase A), 0.1% FA in ACN
(mobile phase B)

Faassen (2013)

LC-MS/MS

NONE

ZIC®-HILIC column
(2.1x150mm, 5μm
diameter)

ACN with 0.1% FA (mobile
phase A), Millipore water with
0.1% FA (mobile phase B)
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Thermo Scientific
Finnigan TSQ
Quantum UltraAM
tandem mass
spectrometer QQQ
Thermo Scientific
Finnigan TSQ
Quantum Ultra
AM tandem mass
spectrometer QQQ
Agilent 1200 LC
and an Agilent
6410A QQQ

Karlsson
(2014)

LC-MS/MS

AQC

Mondo (2014)

LC-MS/MS
and HPLCFLD

AQC

Banack (2014)

LC-MS/MS

AQC

Jiao (2014)

LC-MS/MS

AQC

Baptista (2015)

LC-MS/MS

NONE

ACCQ-TAG™
ULTRA C18 column
(100mmx2.1mm,
1.7μm particle size
column)
LC-MS/MS: BEH
C18 column
(150x2.1mm, 1.7μm)
HPLC-FLD: Waters
Nova-Pak C18 column
(3.9x300mm)

Waters AccQ Tag
Ultra column
(2.1x100mm)
Eclipse XDB-C18
column (4.6x100mm)

ZIC-HILIC
(2.1x100mm, 5μm
diameter) column
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5% ACN in water with 0.3%
acetic acid (mobile phase A),
ACN with 0.3% acetic acid
(mobile phase B)

TSQ Vantage
QQQ

LC-MS/MS: 20mM
ammonium formate with 0.2%
FA (mobile phase A), 0.1%
FA in ACN (mobile phase B)
HPLD-FLD: 140mM sodium
acetate, 5.6mM
trimethylamine, pH 5.7
(mobile phase A), 52@
aqueous ACN (mobile phase
B)
0.1% FA in water (mobile
phase A), 0.1% FA in ACN
(mobile phase B)
28% ACN in water with 0.1%
NH 4 COOH

LC-MS/MS:
Waters Acquity IClass UPLC
system
HPLC-FLD:
Waters 1525
Binary HPLC,
Waters 2475 Multi
λ-Fluorescence
detector
Waters AcquityUHPLC and
Thermo TSQ QQQ
Agilent 1290/6460
HPLC/MS/MS
spectrometry
system with ESI
Thermo LCQ Fleet
Ion Trap LC-MS
system

ACN with 0.1% FA (mobile
phase A), Deionized water
with 0.1% FA (mobile phase
B)

1.5. HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHY
(HILIC)

The HILIC column was first developed and published in by Linden et al. (1975).
Hydrophilic interaction liquid chromatography (HILIC), is typically described as a
variant on normal phase liquid chromatography in which the mobile phase used is less
polar than the stationary phase (Buszewski et al., 2012). Common stationary phases are
similar to those utilized in normal phase liquid chromatography, such as, silica. In
contrast to normal phase liquid chromatography, HILIC employs a mobile phase that is
often used in reverse phase liquid chromatography (Buszewski et al., 2012). The use of
HILIC has become more and more popular as this development allows for the analysis of
small molecules in complex matrices and can be used for ion chromatography to analyze
analytes that are positively or negatively charged (Buszewski et al., 2012). There is some
debate as to how retention is achieved using HILIC, however, the most current
explanation described by Buszewski et al. (2012), is depicted below (Figure 4). On the
basis of Buszewski’s theory, separation is achieved by partitioning, or liquid/liquid
extraction, per say (Buszewski et al., 2012). With a mobile phase composed of
acetonitrile and water, the water forms a layer on the surface of the very hydrophilic
stationary phase (silica) (Buszewski et al., 2012). The acetonitrile forms an additional
layer on top of the aqueous layer (Buszewski et al., 2012). This interaction creates a type
of liquid/liquid attraction in which the analyte moves towards the hydrophilic stationary
phase, being retained within the aqueous layer (Buszewski et al., 2012). On the basis of
the increasing hydrophilicity of the analyte, elution off of the stationary phase of the
column will occur later, separating the analyte from the matrix.
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Figure 4. Proposed mechanism of HILIC separation by Buszewski et al., 2012 (Buszewski et al,
2012).

1.6. MATRIX ASSISTED LASER DESORPTION IONIZATION (MALDI)
Matrix assisted laser desorption ionization (MALDI), is an ionization technique that
requires the sample to be placed in a matrix that protects the sample from being destroyed
by a laser that is applied to the sample/matrix. With MALDI-ToF-MS, a laser is applied
to the sample/matrix, ionizing the sample and allowing the secondary ions to travel
through the flight tube, separating them by mass and charge, and finally analyzing them
by the ToF analyzer (Figure 5). Quantitative amino acid analysis has been done using
MALDI-ToF-MS/MS, however, no research has been published using these techniques
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for the analysis of BMAA, and therefore, operating parameters had to be optimized for
this particular amino acid. Previous research has suggested that BMAA becomes
misincorporated into human proteins by replacing L-serine, and in a study done by
Dunlop, et al. (2013), data provided evidence for this misincorporation. In a study done
by Alterman, et al. (2004) at the University of Kansas, MALDI-ToF-MS/MS proved to
be successful in the quantification and qualification of nineteen (19) amino acids using αcyano-4-hydroxycinnamic acid (CHCA) as the matrix. Other matrices used in this study
included meso-tetra (pentafluorophenyl) porphine (F20TTP), and 2,5-dihydroxybenzoic
acid (DHB), however, with F20TTP and DHB, only 13 and 14 of the amino acids were
observed, respectively (Alterman et al., 2004). Serine was not observed using DHB. On
the basis of the success of this previous study, CHCA was the matrix of choice for the
analysis of BMAA using MALDI-ToF-MS/MS, in addition to the data showing strong
evidence that BMAA is capable of replacing L-serine (Alterman et al., 2004). For the
analysis of amino acids, 1μL of CHCA is typically spotted onto each sample well, and
allowed to dry. Once dry, 1μL of sample is spotted onto each sample well on top of the
dried matrix. The plate is then allowed to air dry, and is then placed into the holder of the
MALDI instrument.
As discussed by Gogichaeva, et al. (2012), the use of MALDI-ToF/ToF-MS/MS as a
qualitative and quantitative method for amino acid analysis, has many advantages over
liquid chromatography. The MALDI-ToF/ToF-MS/MS decreases the data acquisition
time to only a few seconds as opposed to the data acquisition time using LC-MS/MS of
30-45 minutes. This research group also determined that MALDI-ToF/ToF-MS/MS is
capable of distinguishing structural isomers (Gogichaeva et al., 2012). Derivatization and
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chromatographic separation is not necessary with MALDI-ToF-MS, however, many
methods using HPLC and LC-MS/MS require both.

Figure 5. Schematic diagram of MALDI-ToF-MS/MS instrument in reflector mode.
Figure 5 is a rudimentary diagram illustrating a MALDI-ToF-MS instrument used in
reflector mode. Using reflector mode, the sample has more time in the flight tube,
allowing for greater separation of a mixture, to differentiate between isobaric and
isomeric isotopes. In linear mode, isomers cannot be distinguished from each other, and
can lead to an overestimation of an analyte if an isomer is present in the sample.
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1.7. SPECIFIC AIMS
The main objective of this research included laboratory experiments to develop a
quantitative MALDI-TOF/TOF-MS/MS method to detect and quantify BMAA in a
variety of matrices. Through a series of aims, the main objective was achieved. The
aims presented in this study are described as follows:
i.

Adapt/develop an LC-MS/MS method to detect and quantify BMAA in a
variety of matrices

ii.

Develop a MALDI-TOF/TOF-MS/MS method to detect and quantify
BMAA in a variety of matrices

iii.

Synthesize 13C-BMAA to use as an internal standard for both the
MALDI-TOF/TOF-MS/MS and LC-MS/MS method

iv.

Compare quantitative results from LC-MS/MS to that of MALDITOF/TOF-MS/MS

v.

Apply MALDI-TOF/TOF-MS/MS method to biological samples in
search of BMAA incorporation

2. MATERIALS AND SAMPLE PREPARATION
2.1. MATERIALS
Reference standards of L-BMAA hydrochloride was purchased from Sigma
Aldrich (St. Louis, MO), and DL-2,4-DAB dihydrochloride was purchased from Alfa
Aesar (Ward Hill, MA). Amino Acid Standard (AAS) was purchased from Sigma
Aldrich (St. Louis, MO) in a solution of 0.1 N HCl (Table 2). Methyltyrosine was
purchased from Sigma Aldrich (St. Louis, MO). Bovine Serum Albumin (BSA) was
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purchased from Sigma Aldrich (St. Louis, MO). The 13C-BMAA was prepared in house
according to a D 3 -BMAA synthesis by Jiang, et al. (2013) with some modifications (see
below). Acetonitrile, HCl, HPLC grade water, and chloroform were purchased from
Fisher Scientific (Fair Lawn, NJ). Biological tissue samples were provided by Dr. Larry
Brand (Division of Marine Biology and Fisheries, Rosentiel School of Marine and
Atmospheric Science) in 2012, from the Johnson Key Basin, Florida. The standard stock
solutions of both BMAA and DAB in powder form were prepared with HPLC grade
water at 10mg/mL for BMAA and 1mg/mL for DAB, respectively. These stock solutions
were diluted to varying concentrations dependent on sample. For methodology, please
see Chapters 3 and 4.
The matrices, AAS, BSA, and biological tissue samples, were chosen for this
research to demonstrate the validity of a MALDI-TOF/TOF-MS/MS method when
spiking samples in increasingly complex matrices. The biological tissue samples
(shrimp) provide an example of biological tissues from an aquatic system where the
presence of BMAA has been seen in previous studies.
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Table 3. Amino Acid Standard Composition
AMINO ACID

MOLECULAR
FORMULA

CONCENTRATION
(μMoles/mL)

MOLECULAR
WEIGHT

L-Alanine

C 3 H 7 NO 2

2.50

89.09

Ammonium

NH 4 Cl

2.50

53.49

L-Arginine

C 6 H 14 N 4 O 2

2.50

174.2

L-Aspartic Acid

C 4 H 7 NO 4

2.50

133.1

L-Cystine

C 6 H 12 N 2 O 4 S 2

1.25

240.3

L-Glutamic Acid

C 5 H 9 NO 4

2.50

147.1

Glycine

C 2 H 5 NO 2

2.50

75.07

L-Histidine

C6H9N3O2

2.50

155.2

L-Isoleucine

C 6 H 13 NO 2

2.50

131.2

L-Leucine

C 6 H 13 NO 2

2.50

131.2

L-Lysine

C 6 H 14 N 2 O 2

2.50

146.2

L-Methionine

C 5 H 11 NO 2 S

2.50

149.2

L-Phenylalanine

C 9 H 11 NO 2

2.50

165.2

L-Proline

C 5 H 9 NO 2

2.50

115.1

L-Serine

C 3 H 7 NO 3

2.50

105.1

L-Threonine

C 4 H 9 NO 3

2.50

119.1

L-Tyrosine

C 9 H 11 NO 3

2.50

181.2

L-Valine

C 5 H 11 NO 2

2.50

117.2

Chloride
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2.2. SAMPLE PREPARATION
2.2.1. SYNTHESIS OF 13C-BMAA
The synthesis of 13C-BMAA was performed according to a D 3 -BMAA synthesis
by Jiang (2013) with some modifications. Sodium hydroxide (0.22g) was added to a
room temperature solution of (0.25g) 13C-methylamine hydrochloride in 1mL HPLC
grade water and stirred until dissolved. Two-Acetamidoacrylic acid (0.0925g) was then
added to the solution and stirred at room temperature for 10 minutes. The mixture was
then stirred for 22 hours at 35°C. The mixture was cooled back down to room
temperature and the solution was placed in a rotary evaporator to remove methylamine.
The crude product was dissolved in excess 3M HCl (2.0mL), and refluxed for 2 hours at
100°C. After refluxing, the sample was placed in a vacuum centrifuge to remove HCl in
vacuo. The product was recrystallized in an ice bath (~4°C) using ethanol and water.
The crystals were then filtered and washed with cold ethanol four times, and then dried
under vacuum. The final yield of 13C-BMAA was 169.5mg. The NMR spectral data is
consistent with the desired outcome (Figure 7).

Figure 6. Proposed mechanism of 13C-BMAA
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Figure 7. 1H-NMR spectra of unlabeled BMAA (top figure) and 13C-BMAA (bottom
figure). The singlet peak at 3.083 ppm is absent in the unlabeled BMAA.
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2.2.2. MALDI MATRIX
The α-Cyano-4-hydroxycinnamic acid (CHCA) matrix was prepared according to
Gogichaeva et al. (2012) without recrystallization, because of a higher purity compound
that has become available since the publication of the paper. A solution of 8.5mL ACN,
2.47mL water, and 30μL of 10% trifluoroacetic acid was prepared. A 1mL aliquot of this
solution was placed in a 1.5mL vial and CHCA (powdered form) was added until
saturation. The solution was prepared fresh each day of analysis to ensure no degradation
of the matrix.
2.2.3. STANDARDS FOR METHOD DEVELOPMENT
Stock solutions with concentrations of 1mg/mL (1000ppm) of BMAA and DAB
were prepared in HPLC grade water and used for the standard calibration curve, and to
spike AAS, BSA, and biological tissue homogenates for method development. The stock
solutions were diluted to different concentrations depending on the analysis. The
structural isomer DAB, was used as an internal standard for MALDI-TOF/TOF-MS/MS.
Validation procedures were done using BMAA and DAB standards.
2.2.4. BMAA AND AMINO ACID STANDARDS
Stock solutions, 1mL of 100μM AAS were prepared and spiked with 200μM of
methyltyrosine as an internal standard (IS) and increasing concentrations of BMAA (0,
20, 50, 100, and 300μM). The solutions were prepared using HPLC grade water and
stored in a refrigerator at 4°C until analysis.
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2.2.5. BMAA AND BOVINE SERUM ALBUMIN
Two methods of hydrolysis were employed for the analysis of BSA as part of
methods development, and subsequent analysis of tissue samples. In the first method, a
microwave-assisted acid hydrolysis was used. According to previous literature, this
method of hydrolysis vastly reduces the hydrolysis time, while still providing comparable
digestion of proteins (Zhong et al., 2004). For development of this method, 10μL
(1μg/1μL) of aqueous BSA solution was combined with 10μL of 20mM Dithiothreitol
(DTT), varying concentrations of BMAA (0, 20, 50, 100, 120, and 300μM) and constant
concentration of DAB (IS) (100μM) in 1.5mL polypropylene Eppendorf tubes (6 tubes).
The tube was then capped, sealed with tephlon tape and incubated for 20 minutes at
60°C. Once this was complete, the tape was removed and 20μL of 50% (vol/vol)
trifluoroacetic acid (TFA) was added. The Eppendorf tubes were resealed, and placed in
a round bubble rack floating in at least 100mL of distilled water in a round polypropylene
container (Figure 8). The samples were then irradiated for 7.5 minutes in 900 watt
microwave. Once irradiation was complete, samples were dried in vacuo using a
Speedvac at 45°C, and then resuspended in 50μL of 0.1% aqueous formic acid. The
samples were centrifuged at 14,000rpm for 5 minutes to remove particulate matter and
the supernatant was stored at 4°C until analysis with MALDI-TOF/TOF-MS/MS. For
analysis, 1μL of CHCA matrix was spotted onto the MALDI plate, allowed to dry, and
then 1μL of BSA sample was spotted on top of the dried matrix. Each sample was
analyzed and assayed in duplicate.
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Figure 8. Microwave-assisted acid hydrolysis set-up

For the second method of hydrolysis, a more traditional hydrolysis was employed.
Bovine serum albumin (BSA) (0.5g) was weighed out and transferred to 10mL of 6M
HCl and hydrolyzed for 24 hours at 110°C. After hydrolysis, the sample was filtered
using vacuum filtration (Whatman 42.5mm 0 circles, 11μm porosity), and further filtered
with a 25mm syringe filter (Fisherbrand, 0.2μm, PTFE, Non-sterile). The filtered extract
was then transferred to a 25 mL round bottom flask and attached to a rotary evaporator
(BUCHI Rotovapor R-3, Recirculating Chiller F-100, and Vacuum Pump V-700) with
the water bath set at 65°C until dry. The residue was resuspended in 10 mL of HPLC
grade water, and washed with 10 mL of chloroform. The organic layer was discarded,
and the aqueous layer was placed into a 25 mL glass vial and stored at 4°C until analysis.
Samples (40μL) were prepared containing 20μL of CHCA matrix, BSA solution, and
varying concentrations of BMAA and 50ppm DAB (IS). The concentrations for BMAA
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were 0, 10, 25, 50, 75, and 125ppm. Each sample (2μL) was spotted onto a MALDI plate
with two spots for each concentration. All BSA samples were analyzed in duplicate and
quantitation of BMAA was done using MALDI-TOF/TOF-MS/MS.
2.2.6. ANALYSIS OF BIOLOGICAL TISSUES
Biological tissues (shrimp), were collected by Larry Brand in 2011 from the
Johnson Key Basin, ENP, Florida. The tissues were stored in ethyl alcohol prior to
extraction procedures. Tissues were soaked in 500mL MilliQ water for an hour to wash.
Tissue samples were then submerged in liquid nitrogen and homogenized using a
sterilized food processor. Tissue homogenates (1g) were hydrolyzed in 10mL of 6M HCl
for 24 hours at 110°C (Figure 9). After hydrolysis, particulate matter was removed using
vacuum filtration (Whatman 42.5mm 0 circles, 11μm porosity) and further filtered with
25mm syringe filters (Fisherbrand, 0.2μm, PTFE, Non-sterile). Filtered extract was
transferred into ten 1.5mL Eppendorf tubes, 1mL aliquots per tube. The samples were
dried in vacuo using a Speedvac at 45°C. The samples were then spiked with increasing
concentrations of BMAA (0, 1, 10, 75, and 200ppm) and resuspended to 1mL with 0.1%
aqueous formic acid. To remove any residual lipids prior to analysis, the resuspended
extract was washed with 500µL of chloroform. The chloroform layer was then discarded.
Further, a solid-phase extraction (SPE) method developed by Li et al., in 2012 was
adapted for these biological samples (Li et al., 2012). Phenomenex Strata-X-C SPE
33µm Polymeric Strong Cation, 200mg/6mL cartridges were used for an SPE clean-up.
The columns were activated with 5mL of methanol, followed by 5mL of 0.1% formic
acid. The samples (1mL) were then applied to the columns. The samples were washed
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again with 5mL of 1% formic acid, and then 5mL of methanol. Finally, the analyte was
eluted with 5mL of NH 4 OH v/v in methanol and collected in clean, 8mL glass vials. The
samples were then dried under nitrogen and resuspended in 1mL of HPLC grade water.
Each sample was spiked with 25ppm of DAB as an internal standard (IS). The samples
were stored at -4°C until analysis. A schematic of the sample preparation can be seen in
Figure 10. All biological tissue samples were analyzed and assayed in triplicate.
Quantitation of BMAA was performed using MALDI-TOF/TOF-MS/MS and the method
of standard addition.

a
Figure 9. Acid Hydrolysis Apparatus
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Figure 10. Sample preparation schematic of biological tissues with a solid phase
extraction clean-up for the quantitative analysis of BMAA by MALDI-TOF/TOFMS/MS.

3. ANALYSIS BY LC-MS/MS
3.1. INSTRUMENTAL PARAMETERS
The LC-MS/MS analysis was performed using a Shimadzu Prominence LC20AD Ultra-Fast Liquid Chromatograph combined with an AB Sciex QTRAP 5500
Triple-Quadrupole mass spectrometer, equipped with a Turbospray ESI source supplied
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with nitrogen gas. The BMAA was separated from other amino acids using hydrophilic
interaction chromatography (HILIC). A binary gradient system was used with 0.1%
formic acid dissolved in HPLC grade water (mobile phase A), and 0.1% formic acid in
acetonitrile (mobile phase B) with a flow rate of 0.5mL/min. The column temperature
was set at 40°C, while the auto sampler temperature was set at 15°C. The elution
gradient (10 minutes) was as follows: time 0 = 30% A; 0.5min. = 30% A; 5min. = 95%
A; 6.25min. = 95% A; 6.5min. = 5% A; 8min. = 5% A; 8.25min. = 30% A; 10min. =
30% A. Separation was achieved using a Phenomenex Kinetex HILIC 100 x 4.6mm,
2.6μm particle size column. The mass spectrometer was operated in positive mode. The
source temperature was 600°C and the ESI spray voltage was set at 5,500V. Each of the
following values are arbitrary, however, the auxiliary gas setting was 40, the nebulizer
gas setting was 60, and the curtain gas setting was 30.
The protonated molecular ion of BMAA (119.033 m/z) was used as the parent ion
for multiple reaction monitoring (MRM) analysis. The following transitions were
monitored: 119>102 (collision energy of 15V) and 119>76 (collision energy 17V). The
analyte BMAA, was successfully separated from its isomer DAB and 13C-BMAA. As
seen in figure 11, with this LC-MS/MS method, for the first transition (BMAA 119>102,
DAB 119>101, and 13C-BMAA 120>103), BMAA elutes at 5.6 minutes, whereas DAB
elutes at 5.54 minutes, and 13C-BMAA elutes at 5.49 minutes. Peak area and intensity
values for each analysis were exported to Microsoft Excel and processed. Analyses were
done at the Advanced Mass Spectrometry Facility at Florida International University.
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Figure 11. LC-MS/MS spectra of BMAA, DAB, and 13C-BMAA standards.
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3.2. RESULTS/DISCUSSION
3.2.1. ANALYSIS OF STANDARDS
Varying concentrations of BMAA (0, 0.05, 0.1, 0.25, 0.5, and 1.0ppm) were
spiked with 1ppm of 13C-BMAA and 1ppm of DAB. Both DAB and 13C-BMAA were
used as internal standards to determine which would provide a better linearity. Multiple
linear regressions were performed and can be seen in Figures 12-15. Figure 12 describes
the linear regression of BMAA with 13C-BMAA as the internal standard from the first
transition of 119.033>102.2 m/z for BMAA and 120.062>103.1 m/z. The analyte,
BMAA, was expected to elute at 5.49 minutes, whereas 13C-BMAA was expected to elute
at 5.47 minutes. Further, Figure 13 describes the linear regression of BMAA again
with 13C-BMAA as the internal standard with a different transition. The transition used
for BMAA was 119.033>76.1 m/z, whereas the transition for 13C-BMAA was
120.062>103.1 m/z (Figure 13).
Figure 14 shows the linear relationship between BMAA with DAB as the internal
standard from the first transition of 119.033>102.2 m/z for BMAA and 119.033>101.2
m/z for DAB. The analyte, BMAA, was expected to elute at 5.49 minutes, whereas DAB
was expected to elute at 5.52 minutes for this particular transition. Figure 15 also shows
the linear relationship of BMAA with DAB as the internal standard, but with the
transitions of 119.033>76.1 m/z for BMAA and 119.033>101.2 m/z for DAB. The
particular transition just described, provided the greatest linearity with an R2 value of
0.9999. The chromatograms are shown in Figures 16-23 for the calibration standards and
amino acid mixtures.
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Peak Area Ratio (BMAA/13C-BMAA)

Analyte/IS Concentration (ppm) vs. Peak Area Ratio
(BMAA/IS)
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R² = 0.9796
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Figure 12. Representative LC-MS/MS calibration curve for the concentration ratios of BMAA
to 13C-BMAA (IS) in ppm against the peak area ratios of BMAA to 13C-BMAA (IS). The
transitions for BMAA and 13C-BMAA are 119.03>102.2 m/z and 120.062>103.1 m/z,
respectively.

Peak Area Ratio (BMAA/13C-BMAA)

Analyte/IS Concentration (ppm) vs. Peak Area Ratio
(BMAA/IS)
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Figure 13. Representative LC-MS/MS calibration curve for the concentration ratios of BMAA
to 13C-BMAA (IS) in ppm against the peak area ratios of BMAA to 13C-BMAA (IS). The
transitions for BMAA and 13C-BMAA are 119.03>76.1 m/z and 120.062>103.1 m/z,
respectively.
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Analyte/IS Concentration (ppm) vs. Peak Area Ratio
(BMAA/IS)
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Figure 14. Representative LC-MS/MS calibration curve for the concentration ratios of BMAA to
DAB (IS) in ppm against the peak area ratios of BMAA to DAB (IS). The transitions for BMAA
and DAB are 119.033>102.2 m/z and 119.033>101.2 m/z, respectively.
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Figure 15. Representative LC-MS/MS calibration curve for the concentration ratios of BMAA to
DAB (IS) in ppm against the peak area ratios of BMAA to DAB (IS). The transitions for BMAA
and DAB are 119.033>76.1 m/z and 119.033>101.2 m/z, respectively.
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3.2.2. ANALYSIS OF BMAA IN AMINO ACID MATRIX
Varying concentrations of BMAA (0, 0.1, and 0.25) were spiked with 1ppm
of 13C-BMAA and 1ppm of DAB in a 50ppm amino acid solution. Using the calibration
curves above, the fourth linear regression was used to calculate the concentration of
BMAA in each amino acid mixture. The peak areas from the BMAA transition of
119.003>76.1 m/z and DAB transition of 119>101.2 m/z of each spiked sample were
exported to Microsoft Excel where they were processed. The peak area ratios of BMAA
to DAB were calculated for each sample and then substituted into the linear regression
equation from Figure 15. From the calculated value, percent recovery was then
calculated using the equation.
%𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 =

𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 − 𝐶𝐶𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
𝐶𝐶𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

The calculated concentration from the 0.1ppm spike was 0.102ppm which led to a
% recovery of 102%. The calculated concentration from the 0.25ppm spike was
0.248ppm which led to a percent recovery of 99.2%. The calibration using the
isotopically-labeled standard 13C-BMAA was not successful and those transitions could
not be calculated with the amino acid mixture samples. The chromatograms are shown in
Figures 16-23 for the calibration standards and the amino acid mixtures.
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Figure 16. Chromatograms of water blanks, 0ppm BMAA and 0.05ppm BMAA standards with
1ppm spikes of 13C-BMAA and DAB as internal standards. BMAA transitions 119.033>102.2
m/z and 119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z are shown above.
Compliments of the Advanced Mass Spectrometry Facility, FIU.
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Figure 17. Chromatograms of 0.1ppm, 0.25ppm, and 0.5ppm BMAA standards with 1ppm spikes
of 13C-BMAA and DAB as internal standards. BMAA transitions 119.033>102.2 m/z and
119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z are shown above. Compliments
of the Advanced Mass Spectrometry Facility, FIU.
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Figure 18. Chromatograms of 0ppm and 1ppm BMAA standards with 1ppm spikes of 13C-BMAA
and DAB as internal standards and 0ppm BMAA in an amino acid matrix with the same
concentrations of internal standards (13C-BMAA and DAB). BMAA transitions 119.033>102.2
m/z and 119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z are shown above.
Compliments of the Advanced Mass Spectrometry Facility, FIU.
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Figure 19. Chromatograms of 0.1ppm, 0.25, and 0.5ppm BMAA in an amino acid matrix with
1ppm spikes of both internal standards (13C-BMAA and DAB). BMAA transitions
119.033>102.2 m/z and 119.033>76.1 m/z and 13C-BMAA transition 120.062>103.1 m/z are
shown above. Compliments of the Advanced Mass Spectrometry Facility, FIU.
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Figure 20. Chromatograms of water blank, 0.0ppm and 0.05ppm BMAA standards with 1ppm
spikes of 13C-BMAA and DAB as internal standards. BMAA transitions 119.033>102.2 m/z and
119.033>76.1 m/z and DAB transition 119.033>101.2 m/z are shown above. Compliments of the
Advanced Mass Spectrometry Facility, FIU.
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Figure 21. Chromatograms of 0.1ppm, 0.25ppm and 0.5ppm BMAA standards with 1ppm spikes
of 13C-BMAA and DAB as internal standards. BMAA transitions 119.033>102.2 m/z and
119.033>76.1 m/z and DAB transition 119.033>101.2 m/z are shown above. Compliments of the
Advanced Mass Spectrometry Facility, FIU.
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Figure 22. Chromatograms of 0ppm and 1ppm BMAA standards with 1ppm spikes of 13C-BMAA
and DAB as internal standards and 0ppm BMAA in an amino acid matrix with the same
concentrations of internal standards (13C-BMAA and DAB). BMAA transitions 119.033>102.2
m/z and 119.033>76.1 m/z and DAB transition 119.033>101.2 m/z are shown above.
Compliments of the Advanced Mass Spectrometry Facility, FIU.
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Figure 23. Chromatograms of 0.1ppm, 0.25, and 0.5ppm BMAA in an amino acid matrix with
1ppm spikes of both internal standards (13C-BMAA and DAB). BMAA transitions
119.033>102.2 m/z and 119.033>76.1 m/z and DAB transition 119.033>101.2 m/z are shown
above. Compliments of the Advanced Mass Spectrometry Facility, FIU.
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3.3. CONCLUSIONS
The LC-MS/MS data in chapter 3 are in agreeance with current literature using a
HILIC column and underivatized BMAA. The developed method on the AB Sciex
QTRAP 5500 Triple-Quadrupole mass spectrometer successfully separated BMAA from
its structural isomer DAB. By using DAB as an internal standard, exceptional linearity
was achieved. As previously reported in literature, DAB tends to co-occur with BMAA
in nature. With successful separation of the isomers, using DAB as an internal standard
proves to be a valuable internal standard for the quantitation of BMAA. To date, I am
unaware of DAB being used as an internal standard.
The use of 13C-BMAA as an internal standard was unsuccessful. In the
chromatogram for 0ppm BMAA in Figure 16, a peak for BMAA still appeared, however,
this peak is not present in the water blank that was injected prior to and after the samples.
This peak indicates that the 13C-BMAA that was synthesized is not isotopically pure and
did not get completely labeled during the synthesis.
4. ANALYSIS BY MALDI-TOF/TOF-MS/MS
4.1. INSTRUMENTAL PARAMETERS
The MALDI-TOF/TOF-MS/MS analysis was performed using a Bruker Autoflex
III Smartbeam MALDI-TOF/TOF-MS/MS. All spectra were acquired using reflector
mode and operated in positive ion mode. The laser was set at 85% with a detector gain of
25x (1,890V). In order to cover as much of the target area as possible, the random walk
mode was set to complete sample with 300 firing positions per spot, and 900 shots total
per spectra. The frequency of the laser was 200Hz which describes how many shots per
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second occurred. The sample rate was set to 2.00 GS/s for the highest resolution. LIFT
mode was used with the parent mass set to 119.14 Da. The acquisition mode was set to
fragments in order to differentiate between isomers. Data was collected over the mass
range of 80-143. Two to three spots were prepared for each sample. Analyses were done
at the Advanced Mass Spectrometry Facility at Florida International University.
Two methods of matrix deposition were utilized: a dried droplet approach, and a
mixed droplet approach. With the dried droplet approach, 1μL of CHCA matrix solution
was deposited onto a MALDI plate in each individual wells (MTP 384 ground steel, ID
210) (Figure 24). Once dry, a 1μL aliquot of sample is deposited on top of the dried
CHCA spot. With the mixed droplet approach, equal parts of CHCA matrix and sample
were combined and vortexed. Once completely mixed, a 2μL aliquot of matrix/sample
were deposited in each well.

Figure 24. Image of 384 well MALDI Plate.
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Spectral data was exported to flexAnalysis Version 3.4 (Build 70) (Copyright ©
Bruker Daltonik GmbH) where the raw data was processed and peak height (intensity)
and peak area values were determined. The mass list values were then exported to
Microsoft Excel where peak intensity or peak area was plotted against that of
methytyrosine (IS) or DAB (IS). Calibration curves were created for each of the different
analyses (standards, amino acid matrix, BSA matrix, and biological tissue matrix).
4.2. BMAA FULL SCAN ANALYSES
4.2.1. FULL SCAN BMAA ANALYSIS
Varying concentrations of BMAA (0, 20, 60, 800, 100, 200, and 300μM)
were spiked with 200μM of methyltyrosine (IS). The parent ion of BMAA is seen at 119
m/z and the parent ion of the IS is seen at 196 m/z. The spectra can be seen in figure 25.
The mass list values for the peak intensity were exported to Microsoft Excel and the
representative calibration curve can be seen in figure 26. In full scan mode, successful
separation of the BMAA standard and methytyrosine was accomplished. The
representative calibration curve gives an R2 value of 0.9881. A higher R2 value could be
obtained with more replicates.
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Figure 25. Positive Ion MALDI-TOF-MS spectrum of BMAA and methyltyrosine (IS) with
CHCA as the matrix. BMAA Concentrations ranged from 0-300μM and methyltyrosine was at
200μM. The BMAA parent ion is seen at 119 m/z and the methyltyrosine parent ion at 196 m/z.
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Figure 26. Representative calibration curve for the concentrations of BMAA in μM against the
peak intensity ratios of BMAA to methyltyrosine (IS) with CHCA as the MALDI matrix. Parent
ions for BMAA and methyltyrosine were 119 and 196, respectively.

4.2.2. FULL SCAN BMAA ANALYSIS IN AMINO ACID MATRIX
An amino acid matrix was spiked with 200μM methyltyrosine (IS) and varying
amounts of BMAA (0, 20, 50, 100, and 250μM). All spectra were obtained using the
same parameters. Peak intensities and areas were exported to Microsoft Excel and
processed. This set of experiments was performed to determine if the developed
MALDI-TOF-MS method could still successfully quantify BMAA in a more complex
matrix. The linear regression (Figure 27) of peak area intensities of BMAA vs.
methyltyrosine (IS) provide good linearity, with a R2 value of 0.9997. At the completion
of this set of experiments, it was determined to continue with a MALDI-TOF/TOFMS/MS method to attempt to discriminate and quantify BMAA with the presence of one
of its structural isomers, DAB.
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Figure 27. Representative calibration curve for the concentrations of BMAA in μM against the
peak intensity ratios of BMAA to methyltyrosine (IS) in an amino acid matrix, with CHCA as the
MALDI matrix. Parent ions for BMAA and methyltyrosine were 119 and 196, respectively.

4.3. MALDI-TOF/TOF-MS/MS ANALYSES
4.3.1. ANALYSIS OF STANDARDS
Varying concentrations of BMAA (0, 2, 5, 10, 15, 25ppm) were spiked with
25ppm DAB as an internal standard. Methyltyrosine was no longer used as an internal
standard once MALDI-TOF/TOF-MS/MS was used, due to issues with ionizing two
different parent ions at the same time. Structural isomer, DAB, has the same molecular
mass as BMAA, however, has different fragment ions. It was therefore decided that if
samples were spiked with the same concentration of DAB regardless of prior presence of
DAB in a sample, it could be used as an internal standard. These analyses were run in
triplicate for validation procedures. Figure 28 represents the spectra for one replicate of
each concentration. As the concentration of BMAA increases, the intensity of the signal
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at 102 m/z increases. The intensity of the signal of DAB, remains constant. Following
current literature, these fragment ions are specific to each analyte. Figure 29 represents
the representative calibration curve for the average ratio of peak intensities of BMAA and
DAB (IS). The error bars were calculated using the standard deviation. In this linear
regression, a R2 value of 0.9983 is seen, showing good linearity with DAB as an internal
standard. The same parameters were used for each spectra, allowing for consistency and
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Figure 28. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB (IS) with
CHCA as the matrix. BMAA Concentrations ranged from 0-25ppm and the concentration of
DAB was at 25ppm. The BMAA fragment ion is seen at 102 m/z and the DAB fragment ion at
101 m/z.
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Figure 29. Representative calibration curve for the concentrations of BMAA in ppm against the
peak intensity ratios of BMAA to DAB (IS) with CHCA as the MALDI matrix. Parent ions for
BMAA and DAB are 119 and their respective fragments are 102 and 101. Concentrations of
BMAA ranged from (0-25ppm) and the concentration of DAB was 25ppm. Error bars were
calculated using the standard deviation.

4.3.2. ANALYSIS OF 13C-BMAA
Within this set of experiments, the use of 13C-BMAA as an internal standard was
explored. As described in chapter 2, 13C-BMAA was synthesized in our laboratory at
Florida International University. In current literature, deuterated BMAA is often used as
an internal standard. The use of 13C-BMAA as an internal standard could have multiple
benefits: visualization with NMR, more stability than deuterated BMAA, and similar
fractionation to BMAA. In this set of experiments, 13C-BMAA solution was spotted
directly on top of air-dried CHCA matrix and compared to the spectra of a mixture of
300μM BMAA with 100μM DAB. Spectra of the fragment ions of BMAA, DAB,
and 13C-BMAA for the transitions 119>102, 119>101, and 120>103, respectively, can be
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seen in Figure 30. Note that each analyte shows fragmentation peaks that differ by 1 m/z
for this transition. The transitions 119>73 and 119>43.8 for BMAA and 120>74 and
120>44.7 are seen in the spectra of Figure 31.
The percent yield of 13C labelled BMAA was questioned with the LC-MS/MS
data, and was therefore not used as an internal standard for the remainder of the
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Figure 30. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB (top), and 13CBMAA (bottom) with CHCA as the matrix. BMAA Concentration was at 300μM, the
concentration of DAB was 100μM, and the concentration of 13C-BMAA was at 300μM. The
BMAA fragment ion is seen at 102 m/z, DAB at 101 m/z, and 13C-BMAA at 103 m/z.
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Figure 31. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA (top) and 13C-BMAA
(bottom) with CHCA as the matrix. BMAA Concentration was at 300μM and the concentration
of 13C-BMAA was at 300μM. The BMAA fragment ions are seen at 73 m/z and 43.8 m/z,
and 13C-BMAA at 74 m/z and 44.7 m/z.

4.3.3. ANALYSIS OF BMAA IN BSA MATRIX
Bovine serum albumin was hydrolyzed overnight as described in the methodology
section. The hydrolyzed solution was separated into five samples and spiked with 50ppm
of DAB (IS) and increasing concentrations of BMAA (0, 10, 50, 75, and 125ppm). With
this matrix, and this method of hydrolysis, the amount of noise and matrix effects
increased the limit of detection to over 100ppm. The spectra in Figure 32 illustrate the
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amount of noise. The peak shape and resolution rapidly decrease below the BMAA
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Figure 32. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB (IS) in a
hydrolyzed BSA solution with CHCA as the matrix. BMAA concentrations ranged from 0125ppm, and the concentration of DAB in each spectra was 50ppm. The fragment ions are seen
at 102 m/z for BMAA and 101 m/z for DAB. Note that below 125ppm, the peak for BMAA at
102 m/z is split into two peaks at 102 m/z and 103 m/z and the signal intensity is greatly reduced.
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4.3.4. BMAA ANALYSIS IN BIOLOGICAL TISSUES
Hydrolyzed biological tissue solution was separated into five samples and spiked
with 50ppm DAB (IS) and increasing amounts of BMAA (10, 25, 50, 75, and 100ppm).
Two spots of each concentration were deposited onto the MALDI plate. MALDITOF/TOF-MS/MS analysis was performed on the sample with the highest concentration
of BMAA (100ppm). Ionization of the analyte was not possible. The data and spectra
are not included in my thesis, because of the inability to qualify or quantify the analyte of
interest (BMAA) or the internal standard (DAB).
As a result of the inability to ionize the analyte of interest (BMAA) and the
internal standard (DAB), additional biological samples (shrimp) were prepared using a
solid-phase extraction clean-up method that was described in chapter 2. Post SPE cleanup, five samples, comprised of hydrolyzed tissue, spiked with 25ppm DAB (IS) and
increasing concentrations of BMAA (0, 1, 10, 75, and 200ppm) were spotted onto the
MALDI plate. Two spots of each concentration were deposited, using the dried droplet
method. MALDI-TOF/TOF-MS/MS analysis was performed for each concentration in
triplicate.
Figure 33 represents the spectra for one replicate of each concentration. As the
concentration of BMAA increases, the intensity of the signal at 102 m/z increases. The
intensity of the signal of DAB, remains constant. Based on current literature, these
fragment ions are specific to each analyte. Figure 34 represents the representative
calibration curve for the average ratio of peak intensities of BMAA and DAB (IS). The
error bars were calculated using the standard deviation. In this linear regression, a R2
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value of 0.9999 is seen, showing good linearity with DAB as an internal standard. The
same parameters were used for each spectra, allowing for consistency and
reproducibility. The method of standard addition was used to calculate the concentration
of BMAA in the unspiked sample. Based on the linear regression, the unspiked sample
contains ~234ppm BMAA. To relate this back to the original sample, in 1g of biological
tissue (shrimp) collected from the Florida Bay, there is approximately 234µg/g of
BMAA. This value falls within the reported ranges of other studies seen in table 1.

Figure 33. Positive Ion MALDI-TOF/TOF-MS/MS spectrum of BMAA and DAB (IS) in a
hydrolyzed biological tissue (shrimp) with CHCA as the matrix. Spiked BMAA concentrations
ranged from 0-200ppm, and the concentration of DAB in each spectra was 25ppm. The fragment
ions are seen at 102 m/z for BMAA and 101 m/z for DAB.
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Figure 34. Representative standard addition calibration curve for the concentrations of BMAA in
ppm against the peak intensity ratios of BMAA to DAB (IS) with CHCA as the MALDI matrix.
Parent ions for BMAA and DAB are 119 and their respective fragments are 102 and 101. Spiked
concentrations of BMAA ranged from (0-200ppm) and the concentration of DAB was 25ppm.
Error bars were calculated using the standard deviation. The calculated concentration of BMAA
in the unspiked sample is 234.52ppm.

4.4. VALIDATION PROCEDURES
As a result of complications with matrix effects that resulted in increased limits of
detection, validation procedures of the MALDI-TOF/TOF-MS/MS method was
performed using BMAA and DAB (IS) standards in an aqueous solution. The following
validation procedures show proof of concept and proof of method. Varying
concentrations of BMAA (0, 2, 5, 15, and 25ppm) were spiked with 25ppm of DAB as an
internal standard. Each concentration was spotted in triplicate, analyzed, and the data
was exported to Microsoft Excel for processing. Method validation followed protocols
published by the International Conference on Harmonisation of Technical Requirements
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for Registration of Pharmaceuticals for Human Use, entitled Validation of Analytical
Procedures: Text and Methodology Q2(R1).
4.4.1. LIMIT OF DETECTION
The determination of the limit of detection was derived from the standard
deviation of the blank. Five replicates of a blank, air-dried CHCA matrix, were analyzed
using the optimized MALDI-TOF/TOF-MS/MS method with the same parameters as the
other samples. The peak intensities of the analytical background at 102 m/z was exported
to Microsoft Excel (Table 4). These values were used to calculate the mean and the
standard deviation. The standard deviation, in accordance to the analytical background
response of the blank and the mean were used to calculate the limit of detection using the
equation (Figure 35), where σ is the standard deviation, and m is the mean of the peak
intensities of the five blanks at 102 m/z.
𝜎𝜎
𝐿𝐿𝐿𝐿𝐿𝐿 = 3 � �
𝑚𝑚
Table 4. Peak intensities analytical background response at 102 m/z.
BLANK
SAMPLE
#
BLANK 1

PEAK
INTENSITY
AT 102 m/z
4.236

PEAK
INTENSITY
AT 101 m/z
31.682

Ratio
BMAA/DAB

MEAN

STD
DEV

LOD
(ppm)

LOQ
(ppm)

0.134

0.149

0.081

10.318

34.393

BLANK 2

4.139

34.250

0.121

BLANK 3

1.400

21.583

0.065

BLANK 4

4.847

17.019

0.285

BLANK 5

2.084

14.559

0.143
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Figure 35. Representative calibration curve for the concentrations of BMAA in ppm against the
peak intensity ratios of BMAA to DAB (IS) with CHCA as the MALDI matrix. Parent ions for
BMAA and DAB are 119 and their respective fragments are 102 and 101. Concentrations of
BMAA ranged from (0-25ppm) and the concentration of DAB was 25ppm. Error bars were
calculated using the standard deviation. Limit of detection and limit of quantitation were
calculated by the measurement of the ratios of peak intensities of fragment ion 102 m/z over 101
m/z in the background response of the blank (5 replicates).

4.4.2. LIMIT OF QUANTITATION
The determination of the limit of quantitation was also based on the mean and standard
deviation of the blank. The following equation was used to calculate the limit of detection:

𝜎𝜎
𝐿𝐿𝐿𝐿𝐿𝐿 = 10 � �
𝑚𝑚

The value for the limit of quantitation is shown in figure 35.
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4.4.3. ACCURACY
Accuracy was determined using the linear regression. Three concentration values
were chosen (high, medium, and low) and were analyzed in triplicate. The calculated
experimental concentration was found using the equation for the linear regression line
(Figure 35). The mean was then calculated for each concentration and the percent
recovery was calculated using the equation.
% 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 = �

𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝐶𝐶𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 − 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏
� 𝑥𝑥 100
𝐶𝐶𝑡𝑡ℎ𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒

The calculated concentrations for each replicate and their respective means can be
seen in Table 5. The percent recovery values for BMAA using MALDI-TOF/TOFMS/MS are 75.2 - 99.21%.
Table 5. Calculated values for percent recovery.
Concentration

(ppm)
LOW (2ppm)
MEDIUM
(15ppm)
HIGH (25ppm)

Calculated
Concentration
#1 (ppm)
2.36
15.23

Calculated
Concentration #2
(ppm)
2.65
12.76

Calculated
Concentration
#3 (ppm)
0.89
15.88

MEAN
(ppm)

21.27

30.79

23.73

25.26

1.96
14.62

4.4.4. PRECISION
The precision of the MALDI-TOF/TOF-MS/MS method was calculated using the
standard deviation of the above mentioned series of concentrations. The same
concentrations and replicates were used for the calculation of percent of relative standard
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deviation. The standard deviation of each concentration was calculated as well as the
mean. The percent of relative standard deviation was calculated using the equation.
𝜎𝜎
%𝑅𝑅𝑅𝑅𝑅𝑅 = � � 𝑥𝑥100
𝑥𝑥̅

The percent relative standard deviation values for BMAA with MALDITOF/TOF-MS/MS are 11.26-48.14%.
4.4.5. RANGE AND LINEARITY
The linear range of the calibration is from 2ppm to 25ppm as seen in Figure 35.
Linearity was shown to have a coefficient of determination of 0.9983 (Figure 35). Nonlinearity was observed when concentrations went below 0.25ppm, which results in a
decrease of the R2 value.
4.5. CONCLUSIONS
The MALDI-TOF/TOF-MS/MS method proved to be a viable alternative to the
traditional methods such as LC-MS/MS and HPLC of BMAA quantitation and
separation. As shown with standards, an amino acid matrix, and a biological tissue
matrix with SPE clean-up, this method is possible. With standards, detection was
possible down to 0.2ppm and validation methods showed an acceptable percent recovery
range of 75.2-99.21% that would have been increased if a concentration higher than
2ppm would have been used for the lowest concentration. The percent relative standard
deviation again was outside of the acceptable range due to the concentration of the lower
limit. If this concentration would have been increased, the percent relative standard
deviation would have been better.

66

The use of methyltyrosine as an internal standard was successful in full scan,
however, in TOF/TOF-MS/MS, instrumental limitations did not enable both parent ions
(BMAA and methyltyrosine) to be ionized at the same time. As seen in the LC-MS/MS
data, 13C-BMAA was not successful as an internal standard for MALDI for the same
reasons it failed for LC-MS/MS, it proved to not be isotopically pure and/or completely
labeled, resulting in an overestimate of BMAA in a sample. The use of DAB as an
internal standard, however, proved to be a viable option. Since both BMAA and DAB
share the same parent ion of 118.14, the MALDI laser was able to ionize both amino
acids at the same time. As shown in previous literature, common fragment ions of
BMAA and DAB are 102 m/z and 101 m/z, respectively. The data produced using
MALDI-TOF/TOF-MS/MS also shows these fragment ions, and with these fragments,
successful quantitation of BMAA is possible using MALDI-TOF/TOF-MS/MS. The
discrimination capabilities of this method were shown as the method was able to
discriminate between two structural isomers whose fragmentation ions differ by only
1 m/z.
Literature reports levels of BMAA in different matrices to be between 4-350μg/g,
or approximately 4-350ppm (Table 1). With these reported values, the use of MALDITOF/TOF-MS/MS would be a viable option to analyze and quantify BMAA in a variety
of samples. In sections 4.3.3 and 4.3.4, the MALDI-TOF/TOF-MS/MS method was
unable to ionize the analyte in these matrices, until an SPE clean-up method was used.
This proved that sample preparation, including the method of hydrolysis, needed to be
optimized in order to analyze BMAA in a more complex matrix. With the BSA matrix,
the limit of detection for BMAA diminished below 125ppm, and with the biological

67

tissue matrix, no BMAA was detected without an SPE clean-up. After additional cleanup steps, the MALDI-TOF/TOF-MS/MS method was capable of ionizing both BMAA
and DAB in a complex biological matrix. Additionally, the amount of BMAA in the
biological sample was calculated with a high level of confidence, based on the R2 value
of 0.9999 from the linear regression in figure 34.
5.

DISCUSSION
Currently on any given day, there are 30,000 cases of ALS, 5.4 million cases of

Alzheimer’s, and 500,000 Parkinson’s patients in the United States alone, and it is
thought that out of all of these cases, only 10% are inherited (National Institute of
Neurological Disorders and Stroke, 2014). The role of BMAA in neurodegenerative
diseases is still unknown, however, the consumption of water or food sources that contain
this amino acid could account for part of the 90% of unknown causes of these diseases.
With that being said, the development of an analytical platform that is capable of
analyzing and quantifying BMAA in a variety of matrices is essential to understand the
extent of human exposure and toxicity. As the prevalence of neurodegenerative diseases
increases, so does the interest for the study of what might cause these debilitating
diseases.
This study has shown the usefulness and potential of MALDI-TOF/TOF-MS/MS for
the analysis of BMAA and its structural isomer DAB. This method has proven to be a
rapid analysis technique with minimal data processing. In this study, MALDI-TOF/TOFMS/MS instrument parameters were optimized for the analysis of BMAA with a sample
analysis time of seconds. However, there are limitations of MALDI-TOF/TOF-MS/MS
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in the analysis of small molecules. With increasing complexity of matrices, instrument
noise made it difficult and in some cases (biological tissue samples), impossible to detect
the analyte of interest (BMAA) without additional clean-up steps. The possibility of
MALDI-TOF/TOF-MS/MS to separate and resolve mixtures that contain structural
isomers of BMAA with high accuracy and precision is there, however, it is important to
state that additional research is essential for the use of this method as an analytical tool
for the analysis of BMAA and other small molecules.
In terms of LC-MS/MS, although this method is much more sensitive, literature
reports concentrations of BMAA in complex matrices between 0-2,286μg/g, this sensitive
of a method could be somewhat unnecessary. Although LC-MS/MS has a much longer
analysis time, 10-45 minutes per sample, this method has provided significant data in the
study of BMAA. The developed MALDI-TOF/TOF-MS/MS method was able to detect
BMAA down to 0.2ppm. In a complex matrix, this limit of detection would obviously
increase, however, with the concentrations of BMAA reported in current literature,
anything below 10ppm could be useful for the study of BMAA in biological samples.
With further research, MALDI-TOF/TOF-MS/MS could compete with traditional
instrumentation such as LC-MS/MS. This study shows a proof of concept that a
MALDI-TOF/TOF-MS/MS method is possible and application to a real world biological
tissue sample. To combine MALDI-TOF/TOF-MS/MS with MALDI imaging would
result in an analytical platform that would allow for minimal sample preparation, rapid
analysis, and visualization of an analyte in a tissue sample, while also eliminating the
need for derivatization, chromatographic separation, and modification of amino acids.
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All of these attributes cannot be obtained with other instrumentation currently used. All
of these qualities would greatly benefit the study of BMAA in neurodegenerative diseases
and further the current understanding of the mechanism by which BMAA acts, its ability
to biomagnify through the food web, and its role in neurodegenerative diseases.
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